<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H53F1076CB53C47B0A95F8C472DEC0C26" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5228 IH: Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-03-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5228</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180308">March 8, 2018</action-date><action-desc><sponsor name-id="P000034">Mr. Pallone</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the <committee-name committee-id="HBU00">Committee on the Budget</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To strengthen the authorities of the Food and Drug Administration to address counterfeit drugs,
			 illegal and synthetic opioids, and opioid-like substances, and for other
			 purposes.</official-title></form>
	<legis-body id="HBD422CB7CADB4E5DB6E11C4A64B97F7D" style="OLC">
		<section id="HDE45010A1CB044489E41E44B1408D4AC" section-type="section-one"><enum>1.</enum><header>Short title; table of contents</header>
 <subsection id="H08328B13A36D480D82B307C2766B9744"><enum>(a)</enum><header>Short title</header><text display-inline="yes-display-inline">This Act may be cited as the <quote><short-title>Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act</short-title></quote> or the <quote><short-title>SCREEN Act</short-title></quote>.</text> </subsection><subsection id="H2C545FFE9FAA486DA11F363ACC846926"><enum>(b)</enum><header>Table of contents</header><text display-inline="yes-display-inline">The table of contents of this Act is as follows:</text>
				<toc container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration">
					<toc-entry idref="HDE45010A1CB044489E41E44B1408D4AC" level="section">Sec. 1. Short title; table of contents.</toc-entry>
					<toc-entry idref="HF99CF2C7389B46C5AB741F507ECC7E8A" level="section">Sec. 2. Detention, refusal, and destruction of drugs offered for importation.</toc-entry>
					<toc-entry idref="H91E97FE4DF14471D9D3BC6D0A650977A" level="section">Sec. 3. Notification, nondistribution, and recall of adulterated or misbranded drug products.</toc-entry>
					<toc-entry idref="H409392996C5349EA931ECBF559AE07A2" level="section">Sec. 4. Seizure.</toc-entry>
					<toc-entry idref="H761F7CBB8ED14595BCD2E9AC6AA62B8F" level="section">Sec. 5. Single source pattern of shipments of adulterated or misbranded drugs.</toc-entry>
					<toc-entry idref="H6DE335E4AB844E18B493952B7960905E" level="section">Sec. 6. Debarring violative individuals or companies.</toc-entry>
					<toc-entry idref="H084C04E3DCD7401FB22CD18E276BD2BC" level="section">Sec. 7. Account to strengthen efforts of FDA to combat the opioid and substance use epidemic.</toc-entry>
				</toc>
			</subsection></section><section id="HF99CF2C7389B46C5AB741F507ECC7E8A"><enum>2.</enum><header>Detention, refusal, and destruction of drugs offered for importation</header>
 <subsection id="H7BEEC3EEA9814C989C3B788C0AFC8717"><enum>(a)</enum><header>Certain imported products deemed To be drugs</header><text display-inline="yes-display-inline">Section 201(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(g)</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H93DBF4E1AC214A048F99DE2BD656745D" style="OLC">
 <paragraph id="H700544C25D9A41D0825C0F058C94ECCF" indent="up1"><enum>(3)</enum><text display-inline="yes-display-inline">An article being imported or offered for import is deemed to be a drug if it—</text> <subparagraph id="HF98135D111384C08B2A51F97499BA380"><enum>(A)</enum><text display-inline="yes-display-inline">is or contains an active ingredient that is contained within—</text>
 <clause id="H9820F4601E5346BD8801EBA1AB55E5F2"><enum>(i)</enum><text>a drug for which an approval is in effect under section 505 of this Act; or</text> </clause><clause id="H3A8C0BC1BF384C5B99A237D90A8F1225"><enum>(ii)</enum><text>biological product for which a license is in effect under section 351 of the Public Health Service Act;</text>
 </clause></subparagraph><subparagraph id="H25B5C73D54764B9F8151589895234EC7"><enum>(B)</enum><text>is or contains an active ingredient that is contained within a drug or biological product for which an investigational use exemption is in effect under section 505(i) of this Act or section 351(a) of the Public Health Service Act, for which substantial clinical investigations have been instituted, and for which the existence of such investigations has been made public; or</text>
 </subparagraph><subparagraph id="H989C087ED3614BC2A44438CF0EB75105"><enum>(C)</enum><text>is a chemical analog of a drug or biological product described in clause (A) or (B).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HBC1A48B7344B4471A616947CA39CAA5A"><enum>(b)</enum><header>Articles of concern</header> <paragraph id="H1E28DE307B6C429482B65126B191DC40"><enum>(1)</enum><header>Delivery by Treasury to HHS</header><text>The first sentence of section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>) is amended by striking <quote>and cosmetics</quote> and inserting <quote>cosmetics, and potential articles of concern (as defined in subsection (t)), and controlled substances described paragraph (6) in the third sentence of this subsection</quote>.</text>
				</paragraph><paragraph id="HA6364AA5A07C466B907073BCA7F9E6D5"><enum>(2)</enum><header>Repeal of antiquated review process</header>
 <subparagraph id="H989AF2AE0E3C4F5E9B0C75FDE0CE49DB"><enum>(A)</enum><header>Repeal</header><text>The second sentence of section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>) is repealed.</text>
 </subparagraph><subparagraph id="HBD660C85EE634DD89AD25697CBD9AB36"><enum>(B)</enum><header>Technical change to keep numbering of sentences the same</header><text display-inline="yes-display-inline">The first sentence of section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>) is amended by striking <quote>the owner or consignee, who may appear</quote> and inserting <quote>the owner or consignee. The owner or consignee may appear</quote>.</text>
					</subparagraph></paragraph><paragraph id="H1A5F964A8E914FD68ECC7D15F1C3DD8F"><enum>(3)</enum><header>Refused admission</header>
 <subparagraph id="H76DCB7F788384ADDB0AA4505C7FA655F"><enum>(A)</enum><header>In general</header><text>The third sentence of section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>) is amended—</text>
 <clause id="H2575E3CF58CD4D20894A389286555FED"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>If it appears from the examination</quote> and inserting <quote>Subject to subsection (b), if it appears from the examination</quote>; and</text> </clause><clause id="H83819DF065F34AF9B9E4CBB2D8C0D904"><enum>(ii)</enum><text>by striking <quote>then such article shall be refused admission, except as provided in subsection (b) of this section</quote> and inserting <quote>or (5) such article is an article of concern (as defined in subsection (t)), or (6) such article is a controlled substance (as defined in section 102 of the Controlled Substances Act) for which a listing in any schedule is in effect (on a temporary or permanent basis) under section 201 of the Controlled Substances Act, or (7) such article is being imported or offered for import in violation of section 301(cc), then such article may be refused admission, and if it appears such article may not be imported into the United States pursuant to subsection (d) or it appears that the article is a counterfeit drug, then such article shall be refused admission</quote>.</text>
 </clause></subparagraph><subparagraph id="HA2171DE6DB6245D4A9C66A027C88FA21"><enum>(B)</enum><header>Definition of article of concern</header><text display-inline="yes-display-inline">Section 801 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381</external-xref>) is amended by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="H176BAC924EEA498DBBC9B5BF590706A2" style="OLC">
 <subsection id="HE6B5573BB5A145EF9F31F665415DB285"><enum>(t)</enum><header>Article of concern defined</header><text display-inline="yes-display-inline">For purposes of subsection (a), the term <term>article of concern</term> means an article that is or contains a drug or other substance—</text> <paragraph id="H27AD04668F87446D8DB93B13E8A462C8"><enum>(1)</enum><text>for which, during the 24-month period prior to the article being imported or offered for import, the Secretary of Health and Human Services—</text>
 <subparagraph id="H12E2DA155FCB4A8A96479EC1F647F28C"><enum>(A)</enum><text>has requested that, based on a determination that the drug or other substance appears to meet the requirements for temporary or permanent scheduling pursuant to section 201 of the Controlled Substances Act, the Attorney General initiate the process to control the drug or other substance in accordance with such Act; or</text>
 </subparagraph><subparagraph id="H05644D1A973C444DB2651FA45749A305"><enum>(B)</enum><text>has made a determination, following the publication by the Attorney General of a notice in the Federal Register of the intention to issue an order temporarily or permanently scheduling such drug or substance in schedule I of section 202 of the Controlled Substances Act, that such article presents an imminent risk to the public health; and</text>
 </subparagraph></paragraph><paragraph id="H9396DB5002C64AB8AAFCBA44DBED87E1"><enum>(2)</enum><text>with respect to which the Attorney General has not—</text> <subparagraph id="HAED5BEF32CA94D5EA70A7D19A5985FC4"><enum>(A)</enum><text>scheduled the drug or other substance under section 201 of such Act; or</text>
 </subparagraph><subparagraph id="HDDB12A42DB2D4CE68E5AA25685324ACA"><enum>(B)</enum><text>notified the Secretary of Health and Human Services that the Attorney General has made a determination not to schedule the drug or other substance under such section.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph></subsection><subsection id="H09D5A59745844F6F9F9C00F0539AD2EF"><enum>(c)</enum><header>Increasing the maximum dollar amount of drugs subject to destruction</header><text>The sixth sentence in section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>) is amended by striking <quote>except that the Secretary</quote> and all that follows through the two periods at the end and inserting <quote>except that the Secretary of Health and Human Services may destroy, without the opportunity for export, any drug refused admission under this section, if such drug is valued at an amount that is $2,500 or less (or such higher amount as the Secretary of the Treasury may set by regulation pursuant to section 498(a)(1) of the Tariff Act of 1930 or such higher amount as the Commissioner of Food and Drugs may set based on a finding by the Commissioner that the higher amount is in the interest of public health) and was not brought into compliance as described under subsection (b).</quote>.</text>
 </subsection><subsection id="H75FC76A3A2FD4569B13445C77932914F"><enum>(d)</enum><header>Destruction of articles of concern</header><text>The sixth sentence of section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>), as amended by subsection (c), is further amended by inserting before the period at the end the following: <quote>; and the Secretary of Health and Human Services may destroy, without the opportunity for export, any article refused admission under clause (6) of the third sentence of this subsection.</quote>.</text>
 </subsection><subsection commented="no" id="H61B65953EE1B464DBC7EB7C4E0C92654"><enum>(e)</enum><header>Technical amendments</header><text display-inline="yes-display-inline">The seventh, eighth, and ninth sentences of section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>) are amended—</text>
 <paragraph commented="no" id="H619DF02890024E6EBA8DE6032631E370"><enum>(1)</enum><text>by striking <quote>a drug</quote> each place it appears and inserting <quote>an article</quote>; and</text> </paragraph><paragraph commented="no" id="HABC4E0DDD79349508E7EA655C2349D06"><enum>(2)</enum><text>by striking <quote>the drug</quote> each place it appears and inserting <quote>the article</quote>.</text>
 </paragraph></subsection><subsection id="H5FA349CFE6A0435DAC1FCEDC54C3C7E9"><enum>(f)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">The last sentence in section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>) is amended to read as follows: <quote>Clauses (2), (5), and (6) of the third sentence of this subsection shall not be construed to prohibit the admission of narcotic or nonnarcotic drugs or other substances, the importation of which is permitted under the Controlled Substances Import and Export Act.</quote>.</text>
			</subsection></section><section id="H91E97FE4DF14471D9D3BC6D0A650977A"><enum>3.</enum><header>Notification, nondistribution, and recall of adulterated or misbranded drug products</header>
 <subsection id="H093B18FBD75E485D85B4721FE20288B2"><enum>(a)</enum><header>Prohibited Acts</header><text display-inline="yes-display-inline">Section 301 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HC12309F98EFB431A96F438DB3A2B6C1D" style="OLC">
 <subsection id="H82F15E276A6144F3BCD1BF99E8641272"><enum>(eee)</enum><text display-inline="yes-display-inline">The failure to comply with any order issued under section 569D.</text> </subsection><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HEAC44D742E8841CCA8B69B299A411218"><enum>(b)</enum><header>Notification, nondistribution, and recall of adulterated or misbranded drugs</header><text>Subchapter E of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref> et seq.) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HFD0A6097D7C4462B8D8BBAAA2A4F94BE" style="OLC">
					<section id="H8DAB1E83CEDE47AF8FA91888A7BFF88F"><enum>569D.</enum><header>Notification, Nondistribution, And Recall Of Adulterated Or Misbranded Drugs</header>
						<subsection id="H66C216F457FE45DBBA1416A0D7F99BEB"><enum>(a)</enum><header>Order To cease distribution</header>
 <paragraph id="HA50E4CAC91864250971F46C132E90F15"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">If the Secretary has reason to believe that the use or consumption of, or exposure to, a drug may cause serious adverse health consequences or death to humans, the Secretary may issue an order requiring any person who distributes such drug to immediately cease distribution of such drug.</text>
 </paragraph><paragraph id="H773CF04262DD48589187B954840E2A6C"><enum>(2)</enum><header>Action following order</header><text display-inline="yes-display-inline">Any person who is subject to an order under paragraph (1) shall immediately cease distribution of such drug and provide notification as required by such order, and may appeal to the Secretary within 24 hours of the issuance of such order. Such appeal may include a request for an informal hearing and a description of any efforts to recall such drug undertaken voluntarily by the person, including after a request under subsection (b). Except as provided in subsection (c), an informal hearing shall be held as soon as practicable, but not later than 5 calendar days, or less as determined by the Secretary, after such an appeal is filed, unless the parties jointly agree to an extension. After affording an opportunity for an informal hearing, the Secretary shall determine whether the order should be amended to require a recall of such drug. If, after providing an opportunity for such a hearing, the Secretary determines that inadequate grounds exist to support the actions required by the order, the Secretary shall vacate the order.</text>
							</paragraph></subsection><subsection id="H432D0D7C1239417D9F06262F6C7D4A40"><enum>(b)</enum><header>Emergency recall order</header>
 <paragraph id="HA5277FA6D89C4F97B9AABF0430421B5C"><enum>(1)</enum><header>In general</header><text>If the Secretary has credible evidence or information that a drug subject to an order under subsection (a) presents an imminent threat of serious adverse health consequences or death to humans, the Secretary may issue an order requiring any person who distributes such drug—</text>
 <subparagraph id="HFADEFF44F4664F3A80C70520D5AD2AF8"><enum>(A)</enum><text>to immediately recall such drug; and</text> </subparagraph><subparagraph id="H687F0984497241578D7B3C242E91FE43"><enum>(B)</enum><text>to provide for notice, including to individuals as appropriate, to persons who may be affected by the recall.</text>
 </subparagraph></paragraph><paragraph id="H5B813512FA9641A1883DD4E4C7709EBB"><enum>(2)</enum><header>Action following order</header><text display-inline="yes-display-inline">Any person who is subject to an emergency recall order under this subsection shall immediately recall such drug and provide notification as required by such order, and may appeal to the Secretary within 24 hours after issuance of such order. The person subject to an emergency recall order shall conduct the recall notwithstanding the pendency of any such appeal. An informal hearing shall be held as soon as practicable but not later than 5 calendar days, or less as determined by the Secretary, after such an appeal is filed, unless the parties jointly agree to an extension. After affording an opportunity for an informal hearing, the Secretary shall determine whether the order should be amended pursuant to subsection (d)(1). If, after providing an opportunity for such a hearing, the Secretary determines that inadequate grounds exist to support the actions required by the order, the Secretary shall vacate the order.</text>
 </paragraph></subsection><subsection id="H8460D2F31E784B62859B1150B0C32C68"><enum>(c)</enum><header>Notice to consumers and health officials</header><text>The Secretary shall, as the Secretary determines to be necessary, provide notice of a recall order under this section to—</text>
 <paragraph id="H3FB527A792F84848BF57F7FE17922563"><enum>(1)</enum><text>consumers to whom the drug was, or may have been, distributed; and</text> </paragraph><paragraph id="HF2C7D74D94AC48EF85850EEEF4BEE9F5"><enum>(2)</enum><text>appropriate State and local health officials.</text>
							</paragraph></subsection><subsection id="H4F8AFB1304D74A9B99F7CF4F3905CDB5"><enum>(d)</enum><header>Order To recall</header>
 <paragraph id="HB89ABC01944A4F8A9824A8E1E20326CF"><enum>(1)</enum><header>Amendment</header><text>Except as provided under subsection (e), if after providing an opportunity for an informal hearing under subsection (a) or (b), the Secretary determines that an order issued under subsection (a) or (b) should be amended to include a recall of the drug with respect to which the order was issued, the Secretary shall amend the order to require a recall.</text>
 </paragraph><paragraph id="HE24237C0A3EE4E20B27347A4F365C5FA"><enum>(2)</enum><header>Contents</header><text>An amended order under paragraph (1) shall—</text> <subparagraph id="HD2FB4541696D45599B26BA5A4C0CB141"><enum>(A)</enum><text>specify a timetable in which the recall will occur;</text>
 </subparagraph><subparagraph id="HFFC20D3684BC4C76B90786BCAB32C895"><enum>(B)</enum><text>require periodic reports to the Secretary describing the progress of the recall; and</text> </subparagraph><subparagraph id="HAE702469029E44A7B4A870306721138D"><enum>(C)</enum><text>provide for notice, including to individuals as appropriate, to persons who may be affected by the recall.</text>
 </subparagraph></paragraph><paragraph id="H7894D0388F3D409398E19D6BDBF609DF"><enum>(3)</enum><header>Assistance allowed</header><text>In providing for notice under paragraph (2)(C), the Secretary may allow for the assistance of health professionals, State or local officials, or other individuals designated by the Secretary.</text>
 </paragraph><paragraph id="HF3460EF6E97F4D689806E5F8808583BD"><enum>(4)</enum><header>Nondelegation</header><text>An amended order under this subsection shall be ordered by the Secretary or an official designated by the Secretary. An official may not be so designated under this section unless the official is the director of the district in which the drug involved is located, or is an official senior to such director.</text>
 </paragraph></subsection><subsection id="H4E5DF23D8D274D06931CA736F4CFB26B"><enum>(e)</enum><header>Savings clause</header><text>Nothing contained in this section shall be construed as limiting—</text> <paragraph id="HF5C97DB3AF154E908E776163F6F392BF"><enum>(1)</enum><text>the authority of the Secretary to issue an order to cease distribution of, or to recall, an drug under any other provision of this Act or the Public Health Service Act; or</text>
 </paragraph><paragraph id="HDC90437C9EB34BE3974AB23542918465"><enum>(2)</enum><text display-inline="yes-display-inline">the ability of the Secretary to request any person to perform a voluntary activity related to any drug subject to this Act or the Public Health Service Act.</text>
							</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H972E11AC27784D9CB6365F44B1D35D9A"><enum>(c)</enum><header>Drugs subject to refusal</header><text display-inline="yes-display-inline">The third sentence of subsection (a) of section 801 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381</external-xref>), as amended by section 2(b)(C), is further amended by inserting <quote>or (8) in the case of a drug, such drug is subject to an order under section 568 to cease distribution of or recall the drug,</quote> before <quote>then such article shall be refused admission</quote>.</text>
 </subsection><subsection id="H35614E4E29D34C29B1920BE0B1B20923"><enum>(d)</enum><header>Application</header><text>Sections 301(eee) and 569D of the Federal Food, Drug, and Cosmetic Act, as added by subsections (a) and (b), shall apply with respect to a drug as of such date, not later than 1 year after the date of the enactment of this Act, as the Secretary of Health and Human Services shall specify.</text>
 </subsection></section><section id="H409392996C5349EA931ECBF559AE07A2"><enum>4.</enum><header>Seizure</header><text display-inline="no-display-inline">Section 304(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/334">21 U.S.C. 334(b)</external-xref>) is amended by striking the first sentence and inserting the following: <quote>The article, equipment, or other thing proceeded against shall be liable to seizure by process pursuant to the libel, and the procedure in cases under this section shall conform, as nearly as may be, to the procedure in admiralty rather than the procedure used for civil asset forfeiture proceedings set forth in section 983 of title 18, United States Code. On demand of either party any issue of fact joined in any such a case brought under this section shall be tried by jury. A seizure brought under this section is not governed by Rule G of the Supplemental Rules of Admiralty or Maritime Claims and Asset Forfeiture Actions. Exigent circumstances shall be deemed to exist for all seizures brought under this section, and in such cases, the summons and arrest warrant shall be issued by the clerk of the court without court review. </quote>.</text>
 </section><section commented="no" id="H761F7CBB8ED14595BCD2E9AC6AA62B8F"><enum>5.</enum><header>Single source pattern of shipments of adulterated or misbranded drugs</header><text display-inline="no-display-inline">Section 801 of the Federal Food, Drug, and Cosmetic Act is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H9C15CFFBEF514A90A46A8958B2F4B293" style="OLC">
 <subsection commented="no" id="H58849C8A883A4E0FA8A226AF08209418"><enum>(u)</enum><header>Single source pattern of shipments of adulterated or misbranded drugs</header><text>If the Secretary identifies a pattern of adulterated or misbranded drugs being offered for import from the same manufacturer, distributor, or importer, the Secretary may by order choose to treat all drugs being offered for import from such manufacturer, distributor, or importer as adulterated or misbranded unless otherwise demonstrated.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section><section id="H6DE335E4AB844E18B493952B7960905E"><enum>6.</enum><header>Debarring violative individuals or companies</header>
 <subsection id="HE5758773645B42DC95FC8DCA6182D1CD"><enum>(a)</enum><header>Prohibited Act</header><text display-inline="yes-display-inline">Section 301(cc) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331(cc)</external-xref>) is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="HC5E7CD561DE342459162DB511692F07F" style="OLC">
 <subsection id="H1C707CF0227B4583B0243FF28631E53D"><enum>(cc)</enum><text display-inline="yes-display-inline">The importing or offering for import into the United States of an article by, with the assistance of, or at the direction of, a person debarred from such activity under section 306(b)(3).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H8C38AF566FB74BD58A945335F6F1B446"><enum>(b)</enum><header>Debarment</header><text display-inline="yes-display-inline">Section 306(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/335a">21 U.S.C. 335a(b)</external-xref>) is amended—</text> <paragraph id="HCCF6FDC3B1C14C6CACC9F77C5338A770"><enum>(1)</enum><text>in paragraph (1)—</text>
 <subparagraph id="H14CFCFC19C554EDBA14A8161F213158E"><enum>(A)</enum><text>in the matter preceding subparagraph (A), by striking <quote>paragraph (2)</quote> and inserting <quote>paragraph (2) or (3)</quote>;</text> </subparagraph><subparagraph id="H08FBF2B4D8BA4F25B6402700952F184A"><enum>(B)</enum><text>in subparagraph (B), by striking <quote>or</quote> at the end;</text>
 </subparagraph><subparagraph id="H479578FCE04A4F698B6BCA79BBF2B956"><enum>(C)</enum><text>in subparagraph (C), by striking the period at the end and inserting <quote>, or</quote>; and</text> </subparagraph><subparagraph id="H8DB549DDC80F4BEF913214E524F77F34"><enum>(D)</enum><text>by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="HED8CF31207B54FE495C71C5AB7EB93D3" style="OLC">
 <subparagraph id="HF8F7CF612F3044F7A226FE693E3370AE"><enum>(D)</enum><text display-inline="yes-display-inline">a person from importing or offering to import into the United States—</text> <clause id="HD768EA6CBFB04660ACCAACDEAE94C035"><enum>(i)</enum><text display-inline="yes-display-inline">a controlled substance as defined in section 102(6) of the Controlled Substances Act; or</text>
 </clause><clause id="H35E6245C9028418DB6D8AEDFCDF3EB80"><enum>(ii)</enum><text>any article that is regulated by the Food and Drug Administration that is valued at $2500 or less (or such higher amount as the Secretary of the Treasury may set by regulation pursuant to section 498(a)(1) of the Tariff Act of 1930).</text></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="HC145921BF21D4409B1499F248810DA64"><enum>(2)</enum><text>by striking paragraph (3) and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="H7912D4FAE4D24C669A3B9749436920CC" style="OLC"> <paragraph id="H4B14AFDFABFF40409033E06E645BA49F"><enum>(3)</enum><header>Persons subject to permissive debarment; importation</header> <subparagraph id="H31DF0E8CE2C940A19DAF89A02121EF16"><enum>(A)</enum><header>Food</header><text display-inline="yes-display-inline">A person is subject to debarment under paragraph (1)(C) if—</text>
 <clause id="H9E8E280FE4EA4CF48B0223A45E85AE85"><enum>(i)</enum><text>the person has been convicted of a felony for conduct relating to the importation into the United States of any food; or</text>
 </clause><clause id="HA5BE1163E7C0453B993480F25CB9A9B7"><enum>(ii)</enum><text>the person has engaged in a pattern of importing or offering for import adulterated food that presents a threat of serious adverse health consequences or death to humans or animals.</text>
 </clause></subparagraph><subparagraph id="H574562981183417C923EAB3C7548270B"><enum>(B)</enum><header>Importation of drugs</header><text>A person is subject to debarment under paragraph (1)(D) if—</text> <clause id="H8F38258214E5429EB79176351C485BB0"><enum>(i)</enum><text>the person has been convicted of a felony for conduct relating to the importation into the United States of any drug or controlled substance (as defined in section 102 of the Controlled Substances Act); or</text>
 </clause><clause id="HAE3BDD34BD18479AA9520BC80AF90DB1"><enum>(ii)</enum><text>the person has engaged in a pattern of importing or offering for import drugs that are—</text> <subclause id="HC3ECC3CEA970489CBD39854455B82AC4"><enum>(I)</enum><text>adulterated, misbranded, or in violation of section 505; or</text>
 </subclause><subclause id="HEDFCC70A31E14451845B8AF0194304C3"><enum>(II)</enum><text>controlled substances whose importation is prohibited pursuant to section 401(m) of the Tariff Act of 1930.</text></subclause></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection></section><section id="H084C04E3DCD7401FB22CD18E276BD2BC"><enum>7.</enum><header>Account to strengthen efforts of FDA to combat the opioid and substance use epidemic</header>
 <subsection id="H3064610C31E044AFA72050660B276251"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs (referred to in this section as the <quote>Commissioner</quote>) shall use any funds appropriated pursuant to the authorization of appropriations under subsection (c) to carry out the programs and activities described in subsection (d) to strengthen and facilitate the Food and Drug Administration’s efforts to address the opioid and substance use epidemic. Such funds shall be in addition to any funds which are otherwise available to carry out such programs and activities.</text>
			</subsection><subsection id="HC6EE9B787C4046B080C0FF2531CCD78F"><enum>(b)</enum><header>FDA Opioid and Substance Use Epidemic Response Fund</header>
 <paragraph id="H028FDBFCE44949C0993F6E3EA9899879"><enum>(1)</enum><header>Establishment of fund</header><text display-inline="yes-display-inline">There is established in the Treasury an account, to be known as the FDA Opioid and Substance Use Epidemic Response Fund (referred to in this subsection as the <quote>Fund</quote>), for purposes of funding the programs and activities described in subsection (d).</text>
 </paragraph><paragraph id="HA9EF3F67F6334F1591E97F7663444FEB"><enum>(2)</enum><header>Transfer</header><text>For the period of fiscal years 2019 through 2023, $110,000,000 shall be transferred to the Fund from the general fund of the Treasury.</text>
 </paragraph><paragraph id="H0D0BDCB3DEAC477F820A95F68767B565"><enum>(3)</enum><header>Amounts deposited</header><text display-inline="yes-display-inline">Any amounts transferred under paragraph (2) shall remain unavailable in the Fund until such amounts are appropriated pursuant to subsection (c).</text>
				</paragraph></subsection><subsection id="H68697245BC5F4D13BCF46047FA0997D4"><enum>(c)</enum><header>Appropriations</header>
 <paragraph id="H2B2E63F29EE2444D89AE1C45B7375217"><enum>(1)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">For the period of fiscal years 2019 through 2023, there is authorized to be appropriated from the Account to the Food and Drug Administration, for the purpose of carrying out the programs and activities described in subsection (d), an amount not to exceed the total amount transferred to the Account under subsection (b)(2). Notwithstanding subsection (g), such funds shall remain available until expended.</text>
 </paragraph><paragraph id="H57C8AF345BAB4636B1C3D670F6F463BE"><enum>(2)</enum><header>Offsetting future appropriations</header><text display-inline="yes-display-inline">For any of fiscal years 2019 through 2023, for any discretionary appropriation out of the Account to the Food and Drug Administration pursuant to the authorization of appropriations under paragraph (1) for the purpose of carrying out the programs and activities described in subsection (d), the total amount of such appropriations for the applicable fiscal year (not to exceed the total amount remaining in the Account) shall be subtracted from the estimate of discretionary budget authority and the resulting outlays for any estimate under the Congressional Budget and Impoundment Control Act of 1974 or the Balanced Budget and Emergency Deficit Control Act of 1985, and the amount transferred to the Account shall be reduced by the same amount.</text>
 </paragraph></subsection><subsection commented="no" id="HD6B0FADA0CB446E6BDF84151292E0EA0"><enum>(d)</enum><header>Food and Drug Administration</header><text>The entirety of the funds made available pursuant to subsection (c)(1) shall be for the Commissioner of Food and Drugs, pursuant to applicable authorities in the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/201">42 U.S.C. 201</external-xref> et seq.) or the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301</external-xref> et seq.) and other applicable law, to support widespread innovation in non-opioid and non-addictive medical products for pain treatment, access to opioid addiction treatments, appropriate use of approved opioids, and efforts to reduce illicit importation of opioids. Such support may include the following programs and activities:</text>
 <paragraph id="H92B468D178CC47E79B2B4652B723E99A"><enum>(1)</enum><text display-inline="yes-display-inline">Obligating contract funds beginning in fiscal year 2019 for an educational campaign that will—</text> <subparagraph id="H3D786A3D2841477EA129EA56A0CFA58A"><enum>(A)</enum><text>educate patients and their families to differentiate opioid medications;</text>
 </subparagraph><subparagraph id="HE87F449CA40F430AB530EA53EB85B8A9"><enum>(B)</enum><text>raise awareness about preferred storage and disposal methods; and</text> </subparagraph><subparagraph id="H70791E0F50484F74A4BEF7C3CA72395E"><enum>(C)</enum><text>inform patients, families, and communities about medication-assisted treatment options.</text>
 </subparagraph></paragraph><paragraph id="H3CC41DF049644664B66197172026C810"><enum>(2)</enum><text>Building the Food and Drug Administration’s presence in international mail facilities, including through—</text>
 <subparagraph id="HB052C566ECC94E8AB9BE432C33E29B0F"><enum>(A)</enum><text>improvements in equipment and information technology enhancements to identify unapproved, counterfeit, or other unlawful phar­ma­ceu­ti­cals for destruction;</text>
 </subparagraph><subparagraph id="H4C20D144905B45DE9D8DB6F9F9C6FB36"><enum>(B)</enum><text>increased and improved surveillance;</text> </subparagraph><subparagraph id="H294C542BCAAC4A9FBE4AA803EA5D3B9A"><enum>(C)</enum><text>renovations at international mail facility locations; and</text>
 </subparagraph><subparagraph id="H91BAA7E6196E452CBA221423106ECE80"><enum>(D)</enum><text>the purchase of laboratory equipment.</text> </subparagraph></paragraph><paragraph id="H938A71F9B2EA46C8BB777113A165D21D"><enum>(3)</enum><text>Enhancing the identification and targeting of firms and products being offered for import into the United States through review and analysis of websites, imports data, and other sources of intelligence thereby making best use of the Food and Drug Administration’s inspectional and analytical resources.</text>
 </paragraph><paragraph id="HB3B47D993D264D31996F1B20A8AF8961"><enum>(4)</enum><text>Increasing the number of staff to increase the number of packages being examined, ensuring the safety of the staff undertaking this work, and ensuring that packages identified as illegal, counterfeit, misbranded, or adulterated are removed from commerce through available authorities, including administrative destruction.</text>
 </paragraph><paragraph id="HFEB60BCFFDAD44FE9F5CC533D466A8E7"><enum>(5)</enum><text>Enhancing criminal investigations resources (including full-time equivalent employees and equipment), imports surveillance, and international work.</text>
 </paragraph><paragraph id="H0260E0A45704403AB0EF82B930876015"><enum>(6)</enum><text>Obtaining equipment and full-time equivalent employees needed to efficiently screen and analyze products offered for import, including by building data libraries of new substances and analogues to facilitate identification and evaluation of pharmaceutical-based agents and by purchasing screening technologies for use at international mail facilities.</text>
 </paragraph><paragraph id="HD8EE51088E7340BA9B190A6972B8F981"><enum>(7)</enum><text>Operating the Food and Drug Administration’s forensic laboratory facility to ensure adequate laboratory space and functionality for additional work and full-time equivalent employees.</text>
				</paragraph></subsection><subsection commented="no" id="HE8CC8A3BA72247A3816FFEE344EA6292"><enum>(e)</enum><header>Accountability and oversight</header>
				<paragraph commented="no" id="HACB21489A4BB4E4AB11B51BCA79BFEE6"><enum>(1)</enum><header>Work plan</header>
 <subparagraph commented="no" id="HF9AADA1C504E4128BDBB25759A533F9E"><enum>(A)</enum><header>In general</header><text>Not later than 180 days after the date of enactment of this Act, the Commissioner of Food and Drugs shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, a work plan including the proposed allocation of funds appropriated pursuant to the authorization of appropriations under subsection (c) for each of fiscal years 2019 through 2023 and the contents described in subparagraph (B).</text>
 </subparagraph><subparagraph commented="no" id="H144D75E09BA74CFCBFEEB6346BE28214"><enum>(B)</enum><header>Contents</header><text>The work plan submitted under subparagraph (A) shall include—</text> <clause commented="no" id="H6B57CECCDD0C430CB8476FDDF9D812E1"><enum>(i)</enum><text>the amount of money to be obligated or expended out of the Account in each fiscal year for each program and activity described in subsection (d); and</text>
 </clause><clause commented="no" id="HC3DA651A74924BBAB8F79487BC433AC4"><enum>(ii)</enum><text>a description and justification of each such program and activity.</text> </clause></subparagraph></paragraph><paragraph commented="no" id="H8E06E3143CDC4B90BB1D033ECAB89C31"><enum>(2)</enum><header>Reports</header> <subparagraph commented="no" id="H79BF68EBBFB848819E6023D2BB27FDC7"><enum>(A)</enum><header>Annual reports</header><text>Not later than October 1 of each of fiscal years 2020 through 2024, the Secretary of Health and Human Services shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, a report including—</text>
 <clause commented="no" id="H886C0B106D724C38BC1488EE2AFFAF8D"><enum>(i)</enum><text display-inline="yes-display-inline">the amount of money obligated or expended out of the Account in the prior fiscal year for each program and activity described in subsection (d);</text>
 </clause><clause commented="no" id="H7D7B2A9CB90B41FEB9DA90BBC36D0002"><enum>(ii)</enum><text>a description of all programs and activities using funds provided pursuant to the authorization of appropriations under subsection (c); and</text>
 </clause><clause commented="no" id="HB32B46368CE74E0A898CBF95A4BD3CC0"><enum>(iii)</enum><text>how the programs and activities are advancing public health.</text> </clause></subparagraph><subparagraph commented="no" id="HF52379315BF340939FECC022F9761E9A"><enum>(B)</enum><header>Additional reports</header><text>At the request of the Committee on Health, Education, Labor, and Pensions of the Senate, or the Committee on Energy and Commerce of the House of Representatives, the Commissioner shall provide an update in the form of testimony and any additional reports to the respective congressional committee regarding the allocation of funding under this section or the description of the programs and activities undertaken with such funding.</text>
 </subparagraph></paragraph></subsection><subsection commented="no" id="H0E8A38A384B34F059B3C916BFF0028FA"><enum>(f)</enum><header>Limitations</header><text display-inline="yes-display-inline">Notwithstanding any transfer authority authorized by this Act or any appropriations Act, any funds made available pursuant to the authorization of appropriations under subsection (c) may not be used for any purpose other than the programs and activities described in subsection (d) strengthen and facilitate the Food and Drug Administration’s efforts to address the opioid and substance use epidemic.</text>
 </subsection><subsection commented="no" id="H93897262EE1D4374B472A5B360F4E3CF"><enum>(g)</enum><header>Sunset</header><text>This section shall expire on September 30, 2022, except that—</text> <paragraph id="HD818B425636146A89F0FEDFECDA0629A"><enum>(1)</enum><text>this subsection does not apply to reporting under subsection (e)(2); and</text>
 </paragraph><paragraph id="HB3D830844FF14A8BA9A521BA22A73793"><enum>(2)</enum><text>this section shall remain in effect until such time, and to such extent, as may be necessary for the funds transferred by subsection (b)(2) to be fully expended.</text>
				</paragraph></subsection></section></legis-body></bill>


